id
stringlengths 36
36
| text
stringlengths 95
399
| source
stringclasses 1
value |
|---|---|---|
3744ec4a-7bb4-4dc2-96c6-b05d9b6a0623 | meta-analysis of non-randomized cohort studies. Eur J Intern Med, 2021.
[65] O. Phadke, K. Rouster-Stevens, H. Giannopoulos, S. Chandrakasan, and S. Prahalad.
Intravenous administration of anakinra in children with macrophage activation syndrome.
Pediatr Rheumatol Online J, 19(1):98, 2021.
[66] E. Pontali, S. Volpi, A. Signori, G. Antonucci, M. Castellaneta, D. Buzzi, A. Montale, | protocol.txt |
f8f50712-218c-4e3a-84f7-453fbb3d2aba | M. Bustaffa, A. Angelelli, R. Caorsi, E. Giambruno, N. Bobbio, M. Feasi, I. Gueli,
F. Tricerri, F. Calautti, E. Castagnola, A. Moscatelli, G. A. Rollandi, A. Ravelli, G. Cassola,
M. P. Sormani, and M. Gattorno. Efficacy of early anti-inflammatory treatment with high
doses of intravenous anakinra with or without glucocorticoids in patients with severe | protocol.txt |
bbc3ca0a-3a75-4b93-a77f-ca34cbb5fc40 | COVID-19 pneumonia. J Allergy Clin Immunol, 2021.
[67] S. Rajasekaran, K. Kruse, K. Kovey, A. T. Davis, N. E. Hassan, A. N. Ndika, S. Zuiderveen,
and J. Birmingham. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in
PRECISE Protocol Version 1.07
Protocol Version Date: June 16, 2023 | protocol.txt |
9a71f867-f677-49b6-abc6-e60777006975 | The Collaborative Pediatric Critical Care Research NetworkPage 74 of 76 Protocol 90 (Hall, Zuppa and Mourani)
the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ
dysfunction/macrophage activating syndrome in critically ill children*. Pediatr Crit Care
Med, 15(5):401–8, 2014.
[68] F. Randow, W. D. Docke, D. S. Bundschuh, T. Hartung, A. Wendel, and H. D. Volk. In | protocol.txt |
a0a73675-0126-49ab-9528-f81fd2cb2cfc | vitro prevention and reversal of lipopolysaccharide desensitization by IFN-gamma, IL-12,
and granulocyte-macrophage colony-stimulating factor. J Immunol, 158(6):2911–8, 1997.
[69] A. J. Rosenbloom, P. K. Linden, A. Dorrance, N. Penkosky, M. H. Cohen-Melamed,
and M. R. Pinsky. Effect of granulocyte-monocyte colony-stimulating factor therapy on | protocol.txt |
ba7a05f2-2691-4b6f-aae0-ec1eecafbdac | leukocyte function and clearance of serious infection in non-neutropenic patients. Chest,
127(6):2139–50, 2005.
[70] G. S. Schulert, F. Minoia, J. Bohnsack, R. Q. Cron, S. Hashad, E. P. I. Kon, M. Kostik,
D. Lovell, D. Maritsi, P. A. Nigrovic, P. Pal, A. Ravelli, M. Shimizu, V. Stanevicha,
S. Vastert, A. Woerner, F. de Benedetti, and A. A. Grom. Effect of biologic therapy | protocol.txt |
5387c4af-3c5f-4b72-82c9-2c7cb71bfd2a | on clinical and laboratory features of macrophage activation syndrome associated with
systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken), 70(3):409–419, 2018.
[71] B. Shakoory, J. A. Carcillo, W. W. Chatham, R. L. Amdur, H. Zhao, C. A. Dinarello, R. Q.
Cron, and S. M. Opal. Interleukin-1 receptor blockade is associated with reduced mortality | protocol.txt |
aee46e7f-3c41-4129-b2f1-d078f7d550c7 | in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior
phase III trial. Crit Care Med, 44(2):275–81, 2016.
[72] T. P. Shanley, N. Cvijanovich, R. Lin, G. L. Allen, N. J. Thomas, A. Doctor, M. Kalya-
naraman, N. M. Tofil, S. Penfil, M. Monaco, K. Odoms, M. Barnes, B. Sakthivel, B. J. | protocol.txt |
3c0f980d-e8ed-4ce9-ae23-7aefb4fb5b9a | Aronow, and H. R. Wong. Genome-level longitudinal expression of signaling pathways
and gene networks in pediatric septic shock. Mol Med, 13(9-10):495–508, 2007.
[73] C. H. Sibley, N. Plass, J. Snow, E. A. Wiggs, C. C. Brewer, K. A. King, C. Zalewski, H. J.
Kim, R. Bishop, S. Hill, S. M. Paul, P. Kicker, Z. Phillips, J. G. Dolan, B. Widemann, | protocol.txt |
557d6f29-290e-49cf-baef-c2334f90f5ea | N. Jayaprakash, F. Pucino, D. L. Stone, D. Chapelle, C. Snyder, J. A. Butman, R. Wesley,
and R. Goldbach-Mansky. Sustained response and prevention of damage progression in
patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a
cohort study to determine three- and five-year outcomes. Arthritis Rheum, 64(7):2375–86,
2012. | protocol.txt |
0fb481be-63a4-487a-8c43-c2738b318686 | [74] C. J. Smith, H. C. Emsley, C. T. Udeh, A. Vail, M. E. Hoadley, N. J. Rothwell, P. J. Tyrrell,
and S. J. Hopkins. Interleukin-1 receptor antagonist reverses stroke-associated peripheral
immune suppression. Cytokine, 58(3):384–9, 2012.
PRECISE Protocol Version 1.07
Protocol Version Date: June 16, 2023 | protocol.txt |
7e8ee57d-5794-4a07-b1b9-5b16e49ea29f | The Collaborative Pediatric Critical Care Research NetworkProtocol 90 (Hall, Zuppa and Mourani) Page 75 of 76
[75] C. J. Smith, S. Hulme, A. Vail, C. Heal, A. R. Parry-Jones, S. Scarth, K. Hopkins,
M. Hoadley, S. M. Allan, N. J. Rothwell, S. J. Hopkins, and P. J. Tyrrell. SCIL-STROKE
(Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized | protocol.txt |
fbbc9a1f-5278-4fd2-9481-a2e08eee892a | Controlled Phase 2 Trial. Stroke, 49(5):1210–1216, 2018.
[76] M. K. R. Somagutta, M. K. Lourdes Pormento, P. Hamid, A. Hamdan, M. A. Khan,
R. Desir, R. Vijayan, S. Shirke, R. Jeyakumar, Z. Dogar, S. S. Makkar, P. Guntipalli,
N. N. Ngardig, M. S. Nagineni, T. Paul, E. Luvsannyam, C. Riddick, and M. A. Sanchez- | protocol.txt |
902413e4-6970-4721-b37a-e144580f0bc4 | Gonzalez. The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases
of COVID-19: A systematic review and meta-analysis. Infect Chemother, 53(2):221–237,
2021.
[77] N. M. Ter Haar, E. H. P. van Dijkhuizen, J. F. Swart, A. van Royen-Kerkhof, A. El Idrissi,
A. P. Leek, W. de Jager, M. C. H. de Groot, S. Haitjema, D. Holzinger, D. Foell, J. van | protocol.txt |
264d04d0-bbc1-4ada-9c4f-551ddf0de986 | Loosdregt, N. M. Wulffraat, S. de Roock, and S. J. Vastert. Treatment to target using
recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset
systemic juvenile idiopathic arthritis: Results from a five-year follow-up study. Arthritis
Rheumatol, 71(7):1163–1173, 2019.
[78] R. K. Thakkar, R. Devine, J. Popelka, J. Hensley, R. Fabia, J. A. Muszynski, and M. W. | protocol.txt |
ab55eb37-5e08-482d-9458-9fcd4ac5e735 | Hall. Measures of systemic innate immune function predict the risk of nosocomial infection
in pediatric burn patients. J Burn Care Res, 2020.
[79] B. W. Van Tassell, C. R. Trankle, J. M. Canada, S. Carbone, L. Buckley, D. Kadariya,
M. G. Del Buono, H. Billingsley, G. Wohlford, M. Viscusi, C. Oddi-Erdle, N. A. Abouzaki, | protocol.txt |
30ddee44-fd9d-44ee-99d6-340b5a870a5e | D. Dixon, G. Biondi-Zoccai, R. Arena, and A. Abbate. Il-1 blockade in patients with heart
failure with preserved ejection fraction. Circ Heart Fail, 11(8):e005036, 2018.
[80] K. Viele, B. R. Saville, A. McGlothlin, and K. Broglio. Comparison of response adaptive
randomization features in multiarm clinical trials with control. Pharm Stat, 2020. | protocol.txt |
604e15c2-50d7-4148-a6ee-90ed29adb336 | [81] S. L. Weiss, F. Balamuth, J. Hensley, J. C. Fitzgerald, J. Bush, V. M. Nadkarni, N. J.
Thomas, M. Hall, and J. Muszynski. The epidemiology of hospital death following
pediatric severe sepsis: When, why, and how children with sepsis die. Pediatr Crit Care
Med, 18(9):823–830, 2017.
[82] S. L. Weiss, M. J. Peters, W. Alhazzani, M. S. D. Agus, H. R. Flori, D. P. Inwald, S. Nadel, | protocol.txt |
d09341ee-bd2a-42c0-b0e8-0e604759c4fd | L. J. Schlapbach, R. C. Tasker, A. C. Argent, J. Brierley, J. Carcillo, E. D. Carrol, C. L.
Carroll, I. M. Cheifetz, K. Choong, J. J. Cies, A. T. Cruz, D. De Luca, A. Deep, S. N.
Faust, C. F. De Oliveira, M. W. Hall, P. Ishimine, E. Javouhey, K. F. M. Joosten, P. Joshi,
O. Karam, M. C. J. Kneyber, J. Lemson, G. MacLaren, N. M. Mehta, M. H. Moller,
PRECISE Protocol Version 1.07 | protocol.txt |
be28dddd-33c7-4e4c-9716-8415b8f35788 | Protocol Version Date: June 16, 2023
The Collaborative Pediatric Critical Care Research NetworkPage 76 of 76 Protocol 90 (Hall, Zuppa and Mourani)
C. J. L. Newth, T. C. Nguyen, A. Nishisaki, M. E. Nunnally, M. M. Parker, R. M. Paul,
A. G. Randolph, S. Ranjit, L. H. Romer, H. F. Scott, L. N. Tume, J. T. Verger, E. A. | protocol.txt |
ea70eea8-735c-45ab-9d1b-fcdae3f2f9b2 | Williams, J. Wolf, H. R. Wong, J. J. Zimmerman, N. Kissoon, and P. Tissieres. Surviving
Sepsis Campaign International Guidelines for the management of septic shock and sepsis-
associated organ dysfunction in children. Pediatr Crit Care Med, 21(2):e52–e106, 2020.
[83] H. R. Wong, N. Z. Cvijanovich, N. Anas, G. L. Allen, N. J. Thomas, M. T. Bigham, | protocol.txt |
35c63116-4fb1-4ced-8b86-3ea93b9f6ad4 | S. L. Weiss, J. Fitzgerald, P. A. Checchia, K. Meyer, M. Quasney, M. Hall, R. Gedeit,
R. J. Freishtat, J. Nowak, S. S. Raj, S. Gertz, K. Howard, K. Harmon, P. Lahni, E. Frank,
K. W. Hart, T. C. Nguyen, and C. J. Lindsell. Pediatric Sepsis Biomarker Risk Model-II:
Redefining the pediatric sepsis biomarker risk model with septic shock phenotype. Crit
Care Med, 44(11):2010–2017, 2016. | protocol.txt |
3997e73d-2952-4e61-99b0-86adfbe39ef6 | [84] B. B. Yang, S. Baughman, and J. T. Sullivan. Pharmacokinetics of anakinra in subjects
with different levels of renal function. Clin Pharmacol Ther, 74(1):85–94, 2003.
[85] T. Zhan, H. Zhang, A. Hartford, and S. Mukhopadhyay. Modified Goldilocks design with
strict type I error control in confirmatory clinical trials. J Biopharm Stat, pages 1–13,
2020. | protocol.txt |
0997e60e-acc6-44c6-82eb-5e98fbf9f820 | [86] J. J. Zimmerman, R. Banks, R. A. Berg, A. Zuppa, C. J. Newth, D. Wessel, M. M. Pollack,
K. L. Meert, M. W. Hall, M. Quasney, A. Sapru, J. A. Carcillo, P. S. McQuillen, P. M.
Mourani, H. Wong, R. S. Chima, R. Holubkov, W. Coleman, S. Sorenson, J. W. Varni,
J. McGalliard, W. Haaland, K. Whitlock, J. M. Dean, R. W. Reeder, and Life After | protocol.txt |
574e26a4-967b-4950-8913-9ea30e3aa766 | Pediatric Sepsis Evaluation Investigators. Trajectory of mortality and health-related quality
of life morbidity following community-acquired pediatric septic shock. Crit Care Med,
48(3):329–337, 2020.
[87] E. Zittan, I. M. Gralnek, and M. S. Berns. The new proactive approach and precision
medicine in Crohn’s Disease. Biomedicines, 8(7), 2020.
PRECISE Protocol Version 1.07 | protocol.txt |
f35168d3-40c0-4321-a51d-ae6eeb9529ec | Protocol Version Date: June 16, 2023
The Collaborative Pediatric Critical Care Research Network | protocol.txt |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.